Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Shaw

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Plos One|January 30, 2014
Garden and landscape-scale correlates of moths of differing conservation status: significant effects of urbanization and habitat diversityAdam J Bates, Jon P Sadler, Dave Grundy, et al.
BJU International|June 28, 2025
Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinomaMuhammad Ali, Mathias Bressel, David Chang, et al.
European Urology|September 20, 2018
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical TrialShankar Siva, Mathias Bressel, Declan G Murphy, et al.
European Urology Open Science|October 3, 2022
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell CarcinomaCristian Udovicich, Jason Callahan, Mathias Bressel, et al.
International Journal of Radiation Oncology, Biology, Physics|June 25, 2022
Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for OligometastasesShankar Siva, Gavin Jones, Mathias Bressel, et al.
The Lancet. Oncology|February 17, 2019
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trialDavid Ball, G Tao Mai, Shalini Vinod, et al.
Contemporary Clinical Trials Communications|January 25, 2021
A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocolDavid Pryor, Mathias Bressel, Nathan Lawrentschuk, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 1, 2026
Stereotactic Ablative Radiotherapy (SABR) one stop service for lung cancer: A pilot study for early-stage Non-Small-Cell Lung Cancer (NSCLC)Neil D Wallace, Mark Burns, Thomas Devereux, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2025
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL StudyCristian Udovicich, Mathias Bressel, Jamil Manji, et al.
Journal of Paediatrics and Child Health|October 15, 2025
The KiwiDiab First National Paediatric Diabetes Benchmarking Audit: A Report on Children and Adolescents With Diabetes in Aotearoa New Zealand 2023Jonathan Williman, Martin de Bock, Ben Wheeler, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Plos One|January 30, 2014
Garden and landscape-scale correlates of moths of differing conservation status: significant effects of urbanization and habitat diversityAdam J Bates, Jon P Sadler, Dave Grundy, et al.
BJU International|June 28, 2025
Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinomaMuhammad Ali, Mathias Bressel, David Chang, et al.
European Urology|September 20, 2018
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical TrialShankar Siva, Mathias Bressel, Declan G Murphy, et al.
European Urology Open Science|October 3, 2022
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell CarcinomaCristian Udovicich, Jason Callahan, Mathias Bressel, et al.
International Journal of Radiation Oncology, Biology, Physics|June 25, 2022
Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for OligometastasesShankar Siva, Gavin Jones, Mathias Bressel, et al.
The Lancet. Oncology|February 17, 2019
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trialDavid Ball, G Tao Mai, Shalini Vinod, et al.
Contemporary Clinical Trials Communications|January 25, 2021
A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocolDavid Pryor, Mathias Bressel, Nathan Lawrentschuk, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 1, 2026
Stereotactic Ablative Radiotherapy (SABR) one stop service for lung cancer: A pilot study for early-stage Non-Small-Cell Lung Cancer (NSCLC)Neil D Wallace, Mark Burns, Thomas Devereux, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2025
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL StudyCristian Udovicich, Mathias Bressel, Jamil Manji, et al.
Journal of Paediatrics and Child Health|October 15, 2025
The KiwiDiab First National Paediatric Diabetes Benchmarking Audit: A Report on Children and Adolescents With Diabetes in Aotearoa New Zealand 2023Jonathan Williman, Martin de Bock, Ben Wheeler, et al.
Pageof 5